Aromatase inhibitors and breast cancer prevention

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 3, 2012, Pages 325-331

  Litton, Jennifer Keating ^a   Arun, Banu K ^a   Brown, Powel H ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Exemestane; Letrozole; Prevention

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BONE DENSITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER SURVIVAL; CARCINOMA IN SITU; DIARRHEA; DISEASE FREE SURVIVAL; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FRACTURE; GYNECOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INVASIVE CARCINOMA; LIBIDO DISORDER; MEDICAL HISTORY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOEMBOLISM; VAGINAL DRYNESS;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856302992     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.651459     Document Type: Review

References (30)

1. Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-31 (Pubitemid 37376980)
2. Santen R, Brodie H, Simpson E, et al. History of Aromatase: Saga of an important biological mediator and therapeutic target. Endocr Rev 2009;30:343-75
3. Schwarzel WC, Kruggel WG, Brodie HJ; Studies on the Mechanism of Estrogen Biosynthesis. VIII. The Development of Inhibitors of the Enzyme System in Human Placenta. Endocrinology 1973;92:866-80
4. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus Zoledronic Acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91
5. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a Prospective Controlled Study. J Clin Oncol 2008;26:2630-5
6. Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 1992;43:155-9
7. Casper R. Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol 2007;106:71-5 (Pubitemid 47362642)
8. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
9. Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-84 (Pubitemid 44707921)
10. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70
11. The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76
12. The Breast International group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57
13. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008;26:1972-9
14. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment With letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948-55
15. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007;25:2664-70 (Pubitemid 47123171)
16. Hadji P, Asmar L, van Nes J, et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol 2011;137:1015-25
17. Jones S, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Oral presentation at San Antonio Breast Cancer Symposium (SABCS); 11 December 2008; San Antonio, Texas
18. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119-27 (Pubitemid 46158372)
19. Coleman RE, Banks LM, Girgis SI, et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 2010;124:153-61
20. Llombart A, Frassoldati A, Paija O, et al. Immediate administration of Zoledronic Acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 19 October 2011 [epub ahead of print]
21. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000 (Pubitemid 29271743)
22. Available from: www.nsabp.pitt.edu/B-35.asp [Last accessed 14 December 2011]
23. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88 (Pubitemid 28439961)
24. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86 (Pubitemid 20026073)
25. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696-706
26. Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011;29:2327-33
27. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010;28:3090-5
28. Goss PE, Ingle JN, Ales-Martinez J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91
29. Available from: www.ibis-trials.org/about/prevention3.php [Last accessed 14 December 2011]
30. Bevilacqua G, Silingardi V, Marchetti P. Exemestane for the prevention of breast cancer in post-menopausal unaffected carriers of BRACA1/2 mutations: Aromasin Prevention Study (ApreS). Breast Cancer Res Treat 2001;69:Abstract 139